Cara Therapeutics
(NASDAQ) CARA
Cara Therapeutics Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$4.02M
Net Income (TTM)
$13.95M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
CARA News
Is Cara Therapeutics a Buy?
3 Pot Stocks Worth a Second Look
CARA: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Cara Therapeutics
Industry
Pharmaceuticals
Sector
Health CareEmployees
12
CEO
Imran Alibhai, PhD
Website
tvarditherapeutics.comHeadquarters
Stamford, CT 06902, US
CARA Financials
Key Financial Metrics (TTM)
Gross Margin
98%
Operating Margin
-6%
Net Income Margin
-3%
Return on Equity
-1%
Return on Capital
-83%
Return on Assets
-36%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$6.52M
Operating Income
$58.38M
EBITDA
$62.60M
Operating Cash Flow
$60.92M
Capital Expenditure
$1.05M
Free Cash Flow
$61.96M
Cash & ST Invst.
$37.90M
Total Debt
$0.00
Cara Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
-100.0%
Gross Profit
$0.00
-100.0%
Gross Margin
0.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
10
N/A
Net Income
$5.53M
+55.7%
EBITDA
$5.50M
+47.3%
Quarterly Fundamentals
Net Cash
$36.23M
-6.2%
Accounts Receivable
$0.00
-100.0%
Inventory
$0.00
-100.0%
Long Term Debt
$115.00K
-99.7%
Short Term Debt
$113.00K
-96.7%
Return on Assets
-35.74%
N/A
Return on Invested Capital
-82.89%
N/A
Free Cash Flow
$4.26M
+69.6%
Operating Cash Flow
$4.26M
+69.6%